Pricing Log in Create free account

Ensysce Biosciences, Inc. (ENSC) vs XTL Biopharmaceuticals Ltd. (XTLB)

Ensysce Biosciences, Inc. and XTL Biopharmaceuticals Ltd. are both Biotechnology companies. Ensysce Biosciences, Inc. and XTL Biopharmaceuticals Ltd. are of similar size ($7.3M and $7.0M). XTL Biopharmaceuticals Ltd. grew revenue faster over the last twelve months: −12.7% against −39.3%. XTL Biopharmaceuticals Ltd. has the higher net margin (0.00% vs −280.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, XTL Biopharmaceuticals Ltd. leads on 12 and Ensysce Biosciences, Inc. on 3.

Valuation

Metric ENSC XTLB Biotechnology median
P/E n/m n/m 10.60
P/S 0.98 1.07 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 1.01 0.99 9.02
Earnings yield (811.76%) (31.56%) (32.88%)
Free cash flow yield (199.80%) (176.08%) (23.13%)

Profitability

Metric ENSC XTLB Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (281.32%) 0.00% 0.00%
Net margin (280.49%) 0.00% 0.00%
Free cash flow margin (196.76%) 0.00% 0.00%
Return on equity (1,295.01%) 0.00% (51.96%)
Return on assets (295.92%) 0.00% (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ENSC XTLB Biotechnology median
Revenue growth (TTM) (39.29%) (12.71%) 6.76%
EPS growth (last fiscal year) 65.24% (409.84%) 29.88%
Revenue growth, 5-year CAGR 5.21% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ENSC XTLB Biotechnology median
Debt to equity 0.00 (1.83) 0.00
Current ratio 0.70 0.70 4.97
Net debt to EBITDA 0.42 (0.11) 1.01

Dividend

Metric ENSC XTLB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ENSC XTLB Biotechnology median
Market cap 7.02m 7.25m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack